Hetero Aurobindo Vivimed Valsartan Losartan Irbesartan $15.26M Settlement for NDMA Contamination
The Hetero Aurobindo Vivimed Valsartan Losartan Irbesartan $15.26M Settlement for NDMA Contamination settlement offers $15.26M in total to eligible claimants who be an individual in the united states (or its territories/possessions) who paid any amount for retail purchase of at least one covered drug during that drug’s specified coverage period.. The deadline to file is June 2, 2026. Proof of purchase is not required.
Deadline: June 2, 2026
Total amount allocated for all claims
Estimated amount per eligible claim
No proof of purchase needed — anyone eligible can file a claim
The notice encourages documentation but indicates it may not be strictly required. If available, submit proof such as pharmacy receipts, insurance explanation of benefits (EOB) statements, and prescription history records. If you file without documentation, the administrator may review your claim and contact you to provide proof of purchase from your pharmacy.
Settlement Summary
These class action settlements grow out of a major “nitrosamine” controversy involving common blood pressure drugs: generic versions of valsartan, losartan, and irbesartan. Starting in 2018, regulators and manufacturers issued nationwide recalls after tests found trace impurities—NDMA, NDEA, and NMBA—within certain drug products. Nitrosamines are a class of chemical contaminants that many public health authorities treat as probable human carcinogens, raising concerns about whether exposure could increase cancer risk over time, even when contamination levels are low. The litigation consolidated similar claims into a large multidistrict proceeding so courts could handle evidence and allegations across multiple manufacturers efficiently. The lawsuits were filed to recover economic losses—essentially, what consumers and insurers paid for medications that were allegedly contaminated and should not have been sold in the first place. As part of the $15.26 million resolution, three separate settlement funds were created (Hetero for valsartan, Aurobindo for irbesartan, and Vivimed for losartan), all administered through one claim system with a shared deadline of June 2, 2026; the claims focus on retail payment amounts (including copays and out-of-pocket costs) rather than personal injury or medical monitoring. That distinction is significant because it means the settlements do not resolve whether any specific impurity caused harm to a particular person—those injury-related issues are being pursued separately within the same broader MDL—while each defendant denies wrongdoing and disputes that the impurity levels were harmful or carcinogenic. Broader implications include how regulators and the industry manage drug-quality risks: after early nitrosamine findings, the FDA and other authorities pushed manufacturers to investigate root causes, assess affected lots, and implement tighter controls to prevent formation of nitrosamines during production and purification. Similar waves of litigation have followed in other drug categories when contamination, manufacturing changes, or insufficient impurity controls led to recalls and nationwide customer reimbursement claims, reflecting a growing expectation that pharmaceutical quality systems must anticipate and prevent trace-level contaminants before products reach patients. For eligible purchasers, submitting a claim by the deadline is the primary way to access this economic recovery pathway as the court reviews the settlements.
Entities Involved
Related Topics
Eligibility Requirements
- Be an individual in the United States (or its territories/possessions) who paid any amount for retail purchase of at least one covered drug during that drug’s specified coverage period.
- Payments can include copays, out-of-pocket amounts, and other consumer payments.
- Third-party payors (such as health insurers and welfare funds) are included in the class for qualifying purchases.
- For Hetero valsartan: the purchase must involve valsartan finished drug formulations containing Hetero Process III valsartan API sold between May 1, 2018 and July 31, 2018.
- For Aurobindo irbesartan: the purchase must involve irbesartan finished drug formulations manufactured using Aurobindo’s IC Route of Synthesis and purchased from January 1, 2016 to the present.
- For Vivimed losartan: the purchase must involve losartan products sold under the specified Vivimed National Drug Codes (NDCs listed in the notice).
- You may qualify for one, two, or all three settlements depending on which products and purchase dates/NDCs apply.
- Do not qualify if you purchased the drugs only for resale.
- Do not qualify if you are a pharmacy benefit manager (PBM).
- Do not qualify if you are a federal or state government entity, with limited exceptions for certain self-funded government employee benefit plans.
Featured Investigations
Stay Updated
Subscribe to our newsletter for the latest settlement updates and news.
Important Notice About Filing Claims
Submitting false information in a settlement claim is considered perjury and will result in your claim being rejected. Fraudulent claims harm legitimate class members and may result in legal consequences.
If you are unsure about your eligibility for this settlement, please visit the official settlement administrator’s website using the link provided above. Review the eligibility criteria carefully before submitting a claim.
Class Action Champion is an independent information resource and is not affiliated with any settlement administrator, law firm, or court. We provide settlement information as a service to help connect eligible class members with legitimate settlements.